Novocure (NASDAQ: NVCR) announced today that the last patient has been enrolled in the INNOVATE trial, a phase 2 pilot ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE